BioSpace News Archive

Rise in use of NK cells for the treatment of infections & liver diseases, surge in awareness among the population regarding various immunotherapies, and increase in R&D for the development of bi-specific antibody for engaging NK cells to eliminate tumor cells drive the growth of the global NK cell therapeutics market.

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for IO-108, a novel antagonist antibody targeting Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2, also known as ILT4) for the treatment of solid tumors.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav ® oral solution for the treatment of idiopathic hypersomnia in adults.

PharmaCyte Biotech, Inc. today announced the closing of its previously announced underwritten public offering of approximately $15 million.

Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced the appointment of Niamh Pellegrini to the Company’s Board of Directors, effective August 10, 2021.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the quarter ended June 30, 2021.

Adicet Bio, Inc., a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, reported operational highlights and financial results for the second quarter ended June 30, 2021.

Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the second quarter 2021 and provided an operational update.

Iridex Corporation reported financial results for the second quarter ended July 3, 2021.

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, reported results for the second quarter of 2021.